UNSPSC 51392605: Metaraminol bitartrate

This classification denotes an alpha-adrenergic agonist with the molecular formula C9H13NO2.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZC4202M9P3, chemically known as (-)-.alpha.-(1-aminoethyl)-m-hydroxybenzyl alcohol tartrate (1:1) (salt), but more generally known as metaraminol bitartrate, which bears US NIH Compound Identifier 5906. European Medicines Agency schedules metaraminol bitartrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08815MIG.

UNSPSC 51392605 Metaraminol bitartrate is a Commodity code representing pharmaceutical compounds and active ingredients procured by state and local health agencies. However, the recent opportunities tagged to this code show a significant mismatch with the code's nominal scope. The Seminole County, Florida IFB solicits naloxone and drug deactivation systems—finished goods for emergency response and harm-reduction programs—not metaraminol bitartrate itself. The Texas Health and Human Services Commission RFI addresses direct-to-manufacturer prescription programs and pharmacy benefit management strategy, touching on pharmaceutical procurement broadly but not on any specific active pharmaceutical ingredient. State and local governments posting under this code appear to be acquiring finished pharmaceutical products, pharmacy program services, and public health supplies rather than raw chemical compounds or bulk active ingredients. Issuing bodies include county health departments and state health agencies; the recent record shows Seminole County (Florida) and the Texas HHS Commission.

Activity under this code is geographically sparse and does not show sustained procurement volume. The two most recent opportunities are from Florida and Texas, posted in mid-2026 and spring 2026 respectively. The Seminole County IFB (solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually via competitive sealed bid, with quarterly deliveries to Sanford, Florida. The Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) was exploratory market research, not a binding procurement, and targeted information on direct-to-manufacturer pharmacy programs rather than specific products. The code shows limited recent activity and appears to be a low-volume category in state and local procurement, with occasional mis-tagged opportunities that do not reflect the code's intended pharmaceutical-ingredient scope.